Company intelligence / Profile preview

Traws Pharma, Inc.

Newtown, Pennsylvania, United Statestrawspharma.com ↗

Ownership: Public · TRAW
Employees: ~7
Development stage: Phase 1

Overview

Traws Pharma has advanced its lead antiviral program tivoxavir marboxil for bird flu into positive Phase 1 studies with robust preclinical efficacy in animal models against avian influenza and drug-resistant strains. Ratutrelvir for COVID targets Mpro without ritonavir co-administration and narazaciclib for oncology indications has entered Phase 1/2 trials in endometrial cancer[5][6].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

narazaciclib

2 more assets in the full pipeline.

Request access →

Partnerships

SymBio Pharmaceuticals LimitedPint International SAViriom, Inc.Temple University[3][4]

Financials

Market cap: $8.1M
Total revenue: $0
Enterprise value: $5M

Beyond the preview

Go deeper on Traws Pharma, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Traws Pharma, Inc..

Explore the full profile